Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H37NO2 |
Molecular Weight | 383.5668 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC3=C(C=C(O)C=C3)[C@](C)(CCN1C)[C@]2(C)CCC(=O)CCC4CCCC4
InChI
InChIKey=LOYWOYCPSWPKFH-DSNGMDLFSA-N
InChI=1S/C25H37NO2/c1-24-14-15-26(3)23(16-19-9-11-21(28)17-22(19)24)25(24,2)13-12-20(27)10-8-18-6-4-5-7-18/h9,11,17-18,23,28H,4-8,10,12-16H2,1-3H3/t23-,24+,25-/m1/s1
Molecular Formula | C25H37NO2 |
Molecular Weight | 383.5668 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Quadazocine is a substituted hexahydro-2,6-methano-3-benzazocine patented by Sterling Drug Inc. as analgesics and narcotic antagonist. Quadazocine is a potent antagonist of μ opioid receptor, less potent antagonist of κ and δ opioid receptors. In monkeys for whom responding was reinforced by food delivery, quadazocine blocks the rate-decreasing effects of the µ-agonists alfentanil and fentanyl with greater potency than it blocked the rate-decreasing effects of the κ-agonists U69,593
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10435403
rhesus monkey: 0.32, 1, or 3.2 mg/kg
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:48:55 GMT 2023
by
admin
on
Sat Dec 16 04:48:55 GMT 2023
|
Record UNII |
840PPY007V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24847760
Created by
admin on Sat Dec 16 04:48:55 GMT 2023 , Edited by admin on Sat Dec 16 04:48:55 GMT 2023
|
PRIMARY | |||
|
840PPY007V
Created by
admin on Sat Dec 16 04:48:55 GMT 2023 , Edited by admin on Sat Dec 16 04:48:55 GMT 2023
|
PRIMARY | |||
|
71076-28-3
Created by
admin on Sat Dec 16 04:48:55 GMT 2023 , Edited by admin on Sat Dec 16 04:48:55 GMT 2023
|
PRIMARY |